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Abstract: Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality among
women. Two-thirds of patients present at advanced stage at diagnosis, and the estimated 5 year
survival rate is 20–40%. This heterogeneous group of malignancies has distinguishable etiology
and molecular biology. Initially, single-gene sequencing was performed to identify germline DNA
variations associated with EOC. However, hereditary EOC syndrome can be explained by germline
pathogenic variants (gPVs) in several genes. In this regard, next-generation sequencing (NGS)
changed clinical diagnostic testing, allowing assessment of multiple genes simultaneously in a faster
and cheaper manner than sequential single gene analysis. As we move into the era of personalized
medicine, there is evidence that poly (ADP-ribose) polymerase (PARP) inhibitors exploit homologous
recombination (HR) deficiency, especially in breast cancer gene 1 and 2 (BRCA1/2) mutation carriers.
Furthermore, extensive preclinical data supported the development of aurora kinase (AURK)
inhibitors in specific tumor types, including EOC. Their efficacy may be optimized in combination
with chemotherapeutic or other molecular agents. The efficacy of metformin in ovarian cancer
prevention is under investigation. Certain mutations, such as ARID1A mutations, and alterations
in the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway, which are specific in ovarian
clear cell carcinoma (OCCC) and endometrioid ovarian carcinoma (EnOC), may offer additional
therapeutic targets in these clinical entities. Malignant ovarian germ cell tumors (MOGCTs) are rare
and randomized trials are extremely challenging for the improvement of the existing management
and development of novel strategies. This review attempts to offer an overview of the main aspects
of ovarian cancer, catapulted from the molecular mechanisms to therapeutic considerations.
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1. Introduction
Approximately 22,440 newly diagnosed cases of ovarian cancer and 14,080 deaths occurred in
the United States in 2017 [1]. Only 10% of ovarian cancers are non-epithelial malignant ovarian germ
cell tumors (MOGCTs) and sex cord-stromal cell tumors (SCSTs) (5% each). Epithelial ovarian cancer
(EOC) differs in epidemiology, etiology, and treatment. Patients diagnosed with EOC should be tested
for hereditary susceptibility genes [2]. Beyond germline pathogenic variants (gPVs) in breast cancer
genes 1 and 2 (BRCA1/2), alterations in BRIP1, RAD51C, and RAD51D and mismatch repair (MMR)
genes also enhance EOC risk. Next-generation sequencing (NGS)-based mutation panels profile
multiple genes simultaneously, allowing the reporting of numerous genes while saving labor and
resources. The identification of homologous recombination (HR)-deficient EOC has significant clinical
implications related to the therapeutic choices of either chemotherapeutic or targeted agents. Indeed,
patients with BRCA mutations or HR deficiency may be treated with maintenance poly (ADP-ribose)
polymerase (PARP) inhibitors in first-line settings or at recurrence. Currently, olaparib, rucaparib,
and niraparib have been approved by the Food and Drug Administration (FDA) and/or European
Medicines Agency (EMA) for the treatment of EOC [3]. Furthermore, aurora kinases (AURKs) are
serine/threonine kinases essential for the onset and progression of mitosis and seem to be promising
prognostic factors for EOC among other cancers. AURKs have been shown to interact with DNA repair
mechanisms and other cell cycle regulators, and could be novel therapeutic targets. Metformin has
anti-angiogenic activity in vivo and chemosensitizing effects in vitro in ovarian cancer; nevertheless,
epidemiological studies on its use in ovarian cancer are not equally promising as compared with
preclinical evidence. The prevalence of ovarian cancer in women with endometriosis is higher than
sporadic ovarian cancer. Endometriosis is frequently described in association with ovarian clear cell
carcinoma (OCCC) and endometrioid ovarian carcinoma (EnOC). Epigenetics may be implicated in the
pathogenesis of endometriosis, whereas DNA methylation serves as an epigenetic biomarker for EOC.
Unlike EOC, MOGCTs typically occur in the first three decades of life. Surgery and platinum-based
chemotherapy remain the standard of care. Even in advanced-stage disease, patients have a high
chance to be cured. MOGCTs rarely develop genetic mutations. The aim of this article is to provide a
comprehensive overview of the genetic and therapeutic evolution of EOC and MOGCTs.
2. Genomic Profiling of EOC by NGS
Recently, microarray technologies have been used to elucidate the complexity of genomic
alterations of EOC. NGS technology has become widely available to determine a patient’s precise
genetic profiling and identify novel mutations for new drug targets. In this context, patients with
EOC with BRCA mutations or HR deficiency experience therapeutic benefit from platinum agents and
PARP inhibitors, whereas immune checkpoint inhibitors are effective in tumors with microsatellite
instability [4,5]. Furthermore, the costs to test multiple genes in a pan-cancer panel are lower as
compared to sequencing isolated genes sequentially [6].
Importantly, multigene panels decrease the chances of missing out on a pathogenic mutation.
When a limited number of genes are tested based on clinical indication and results are negative,
targetable mutations in untested genes cannot be fully excluded. This risk is even higher in cases
of moderate-penetrance genes for which clinical phenotype is less clear, as well as in those without
typical presentation or relevant family history [7].
HR is crucial for carcinogenesis. Single-strand DNA breaks (SSBs) are normally repaired by MMR,
base excision repair, and nucleotide excision repair, in which PARP1/2 have a key role [8]. Inhibition of
these proteins leads to single-strand break accumulation and, consequently to double-strand DNA
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breaks (DSBs) and cytotoxicity. Unlike PARP2, PARP1 can also mediate the repair of DSBs and regulates
the rate of DNA replication fork progression in replication stress [9]. DSBs are repaired either through
HR or through non-homologous end joining (NHEJ)—the choice of which is determined by cell cycle
phase and chromatin context [10]. NHEJ is the preferred mechanism for repair of DSBs in G1 when a
DNA template that could be used for HR is absent.
HR deficiency can be assessed by the presence of germline and somatic mutations in HR genes using
tumor sequencing. However, if mutations in susceptibility genes are ruled out by tumor sequencing,
no additional test is required [11]. Furthermore, HR deficiency leads to the occurrence of genomic scars,
represented by the loss of heterozygosity (LOH), large-scale state transitions (LSTs), and telomeric allele
imbalance (TAI). Two commercial genomic scar assays identify tumors with HR deficiency. “Myriad’s
myChoice HRD assay tests for the presence of LOH, TAI, and LSTs across the genome [12]”. A tumor
with an HRD score of 42 and above is labeled as HRD positive. The “FoundationFocus™ CDx BRCA
LOH” detects mutations in the BRCA1/2 and the percentage of the genome affected by LOH in DNA
from tumor tissue samples [13]. Tumors are considered LOH-high if the score is 16 and above.
In addition to mutations in the BRCA1/2 genes, genomic alterations involving other genes in HR
pathways have been recognized, including Fanconi anemia genes (BRIP1, PALB2), the core RAD genes
(RAD51C, RAD51D), and genes involved in HR pathways either directly (CHEK2, BARD1, NBN, ATM)
or indirectly (cyclin-dependent kinase (CDK) 12) [4]. However, their real effect over assessment of EOC
risk is still uncertain. Genome-wide association studies identified single-nucleotide polymorphisms
associated with susceptibility for EOC. The 27 loci associated with invasive EOC identified so far
account for 6.4% of the polygenic risk for EOC [14].
RAD51C loss-of-function gPVs are rare among EOC patients, with their prevalence varying
between 0.3% and 1.1% [15]. The lifetime risk of EOC among RAD51C carriers is approximately
5% [15]. Both RAD51C and RAD51D are EOC susceptibility genes that are characterized by a reduced
magnitude when compared to BRCA1/2. The increased EOC risk for RAD51C and RAD51D supports
their addition to criteria for risk-reducing salpingo-oophorectomy [16]. Furthermore, genetic defects in
these genes can function as biomarkers for PARP sensitivity.
Clinical testing for PALB2 in EOC is not currently recommended. The majority of studies reported
relative risks that ranged from 0.9 to 5.5 and lacked statistical power [17]. A study analyzing data from
524 families with PALB2 gPVs from 21 countries reported that the estimated risk of EOC at age 80 years
was 5% (95% CI, 2–10%) [18]. For PALB2 carriers, risk-reducing surgery should be recommended for
cases with strong family history of EOC. The predictive value of PALB2 is supported by the evidence
that PALB2-associated tumors respond to platinum-based chemotherapy and PARP inhibitors [4].
Several gPVs in the so-called moderate- and low-penetrance genes, such as BRIP1, have been
reported to be correlated with a moderate lifetime risk of EOC. The prevalence of BRIP1 gPVs among
familial EOC patients can reach 0.7% [19]. The cumulative lifetime risk of EOC diagnosis among BRIP
mutants has been estimated as 5–5.8% [17], predominantly following menopause. The elevated risk of
EOC diagnosis justifies the recommendation for risk-reducing oophorectomies among asymptomatic
carriers and this should be guided based on family history and individual’s preference.
Other hereditary cancer syndromes are also associated with EOC. A lack of MSH2, substantial
mutations in the MLH1 or MSH2 genes, MLH1-methylation inactivation, and transcriptional silencing
lead to Lynch syndrome [20]. MMR deficiency has been demonstrated in 20–40% of endometrial
cancers [21,22], but data on its prognostic value are controversial [21,23,24]. Table 1 reports the
frequency and EOC risk of well-established moderate- and high-penetrance susceptibility genes for
EOC, whereas Table 2 depicts clinical trials of PARP inhibitors in EOC and their therapeutic potential
in patients with HR deficiency.
J. Pers. Med. 2020, 10, 41 4 of 20
Table 1. Impact of moderate- and high-penetrance genes for EOC.
Gene Histologic Subtype Frequency of GermlinePathogenic Variants Lifetime Risk of EOC
BRCA1
HGSOC
3–15% 39–63%
BRCA2 3–6% 17–27%
RAD51C 0–2% 5.2–9%
RAD51D 0–1% 10–12%
BRIP1 0–2% 5.8%
MMR genes (MLH1,
MSH2, MSH6, PMS2)
1. Endometrioid;
2. Clear-cell 0–1% 4–12%
EOC: epithelial ovarian cancer; HGSOC: high-grade serous ovarian cancer; MMR: mismatch repair.
Table 2. Clinical trials of EOC patients with homologous recombination (HR) deficiency.
Study Population Treatment Arms Median PFS HR p
SOLO-1
Newly diagnosed stage
III/IV high-grade EOC,
BRCA1/2 mutated,
maintenance setting
Arm A: Olaparib
Arm B: Placebo
PFS rate at 3 y,
Arm A: 69%
Arm B: 35%
0.28 <0.001
SOLO-2
Platinum-sensitive
relapsed EOC,
BRCA1/2 mutated,
maintenance setting
Arm A: Olaparib
Arm B: Placebo
Arm A: 19.1 m
Arm B: 5.5 m 0.30 <0.0001
SOLO-3 Recurrent EOC,gBRCAm
Arm A: Olaparib
Arm B: CTH of
physician’s choice
Arm A: 13.4 m
Arm B: 9.2 m 0.62 0.013
NOVA
Recurrent EOC,
previous response to
platinum-based CTH,
maintenance setting
Arm A: Niraparib
Arm B: Placebo
gBRCAm cohort,
Arm A: 21 m
Arm B: 5.5 m
0.27 <0.001
Non-gBRCAm cohort with HRD,
Arm A: 12.9 m
Arm B: 3.8 m
0.38 <0.001
Overall non-gBRCAm cohort,
Arm A: 9.3 m
Arm B: 3.9 m
0.45 <0.001
ARIEL 3
Recurrent EOC,
previous response to
platinum-based CTH,
maintenance setting
Arm A: Rucaparib
Arm B: Placebo
Patients with BRCA mutations,
Arm A: 16.6 m
Arm B: 5.4 m
0.23 <0.0001
Patients with HRD,
Arm A: 13.6 m
Arm B: 5.4 m
0.32 <0.0001
ITT population,
Arm A: 10.8 m
Arm B: 5.4 m
0.36 <0.0001
PAOLA 1
Newly diagnosed stage
III/IV high-grade EOC,
BRCA1/2 mutated,
responders to first line
platinum-taxane CTH +
bevacizumab
Arm A: Bevacizumab
+ olaparib
Arm B: Bevacizumab
+ placebo
Overall population,
Arm A: 22.1 m
Arm B: 16.6 m
0.59
<0.001
Patients with HRD, including
those with BRCA mutations,
Arm A: 37.2 m
Arm B: 17.7 m
0.33
Patients with HRD, without BRCA
mutations,
Arm A: 28.1 m
Arm B: 16.6 m
0.43
EOC: epithelial ovarian cancer; PFS: progression-free survival; y: year; m: month; CTH: chemotherapy; HRD:
homologous recombination deficiency; HR: hazard ratio; ITT: intention to treat population.
Overall, for EOC patients, guidelines recommend testing for moderate- or high-penetrance
BRCA1/2, RAD51C, RAD51D, BRIP1, and mismatch repair genes. Cascade testing should be offered to
relatives of carriers of gPVs. Gene sequencing can provide results with different biological meanings.
A genetic alteration can be pathogenic or likely pathogenic, benign or likely benign, or finally of
uncertain significance. The latter represents the main challenge when interpreting genetic alterations.
In a large retrospective cohort of individuals who had genetics testing, 7.7% of unique gPVs of
uncertain significance were reclassified. The majority of them (91.2%) were considered benign or
likely benign [25]. Similarly, in a study on reinterpretation of BRCA1/2 gPVs of uncertain significance,
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93.7% of the reclassified variants were benign or likely benign [26]. Despite this, gPVs of uncertain
significance can be a great source of distress for patients and their families.
Although less prevalent, some non-epithelial ovarian cancers also have their risk enhanced by
genetic factors. DICER1 syndrome, characterized by germline truncating DICER1 mutations includes
predisposition to pleuropulmonary blastoma and Sertoli–Leydig cell tumors [27]. Germline mutations
in STK11 cause Peutz–Jeghers syndrome and are also associated with SCSTs [28].
3. Clinical Development of PARP Inhibitors
PARP inhibitors were originally developed for cancer treatment as radio- and chemosensitizing
drugs. In 2014, the EMA approved a capsule formulation of olaparib as maintenance treatment
in platinum-sensitive, BRCA-mutated (germline and/or somatic), high-grade serous EOC (stydy 19,
NCT00753545) [29]. A few months later, the FDA approved olaparib capsules for the treatment
of patients with deleterious or suspected deleterious germline BRCA-mutated advanced EOC,
who have been treated with three or more prior lines of chemotherapy (stydy 42, NCT01078662) [30].
A tablet formulation of olaparib with improved bioavailability has been developed to facilitate
olaparib administration to patients. It was approved by both agencies for the maintenance
therapy of platinum-sensitive recurrent EOC regardless of BRCA mutational status (SOLO-2,
NCT01874353) [29,31]. FDA approval of olaparib maintenance treatment in 2018 was supported
by the SOLO-1 trial (NCT01844986), examining the efficacy of olaparib vs. placebo in patients with
BRCA-mutated advanced EOC who responded to first-line platinum-based chemotherapy [32].
Rucaparib was approved by the FDA in 2016 and by the EMA in 2018 for patients with deleterious
BRCA mutation (germline and/or somatic)-associated EOC who have been treated with two or more
lines of chemotherapy. The efficacy was supported by a pooled analysis of two single-arm clinical trials:
study 10 (NCT01482715) and ARIEL 2 (NCT01891344) [33–35]. ARIEL 2 enrolled platinum-sensitive
EOC patients, assigned to one of three HR deficiency categories assessed on the most recent collected
tumor sample: BRCA1/2 mutated, BRCA wild-type (BRCAwt) with LOH high, and BRCAwt with
LOH low, respectively [32,34]. The median progression-free survival (PFS) was significantly longer
in the BRCA-mutated subgroup (12.8 months; HR = 0.27, p < 0.0001) and in the BRCAwt/LOH high
(5.7 months; HR = 0.62, p = 0.011), as compared to the BRCAwt/LOH low subgroup (5.2 months).
Similarly, the objective response rate was higher in the BRCA1/2 mutated and BRCAwt/LOH high
subgroups, than the BRCAwt/LOH low subgroup (80%, 29%, and 10%, respectively). Genomic LOH
was shown to be a better predictor of response to rucaparib in patients with BRCAwt tumors with a
sensitivity of 78%, compared to mutations in other HR deficiency genes (sensitivity 11%, p < 0.0001) or
methylation of BRCA1 or RAD51C (sensitivity 48%, p < 0.021). However, by combining mutations in
HR deficiency genes and methylation of BRCA1 or RAD51C, no statistically different sensitivity was
observed (sensitivity 59%, p = 0.13).
In March 2017, the FDA approved niraparib as maintenance treatment of recurrent EOC in
responders to platinum-based chemotherapy (NOVA trial, NCT01847274) [36]. Equally, in November
2017, the EMA approved niraparib for the maintenance treatment of patients with platinum-sensitive
relapsed high-grade serous EOC who responded to platinum-based chemotherapy. In October 2019,
the FDA approved niraparib for patients with advanced HR-deficient EOC treated with at least three
prior chemotherapy regimens based on the results of the Quadra trial (NCT02354586) [37].
Apart from the already approved PARP inhibitors for the treatment of EOC in different settings,
veliparib and talazoparib are in earlier clinical development [38,39]. Veliparib was evaluated mainly
combined with chemotherapy or targeted agents, whilst at least in vitro talazoparib demonstrates
more potent anti-tumor activity based on its enhanced PARP-DNA trapping ability.
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Although PARP inhibitors oppose the catalytic activity of PARP in general, there are remarkable
differences in their abilities to trap PARP based on the size and structure of each separate molecule [40].
This results in significant differences in doses among PARP inhibitors. It has been demonstrated that
PARP trapping is associated with PARP inhibitor cytotoxic activity.
Recently, combination therapy of PARP and immune checkpoint inhibitors is being developed
based on the immuno-regulatory effects of PARP inhibition. MEDIOLA (NCT02734004) is a phase
II study of olaparib and durvalumab in patients with relapsed, platinum-sensitive, BRCA-mutated
EOC, which reported an overall response rate of 72% [41]. The phase I/II TOPACIO study
(NCT02657889) investigated the combination of niraparib and pembrolizumab in patients with
platinum resistant/refractory EOC [42]. The overall response and the disease control rates were 18%
and 65%, respectively. There was no difference in response by BRCA and HR deficiency status.
4. AURKs in Ovarian Cancer
AURKs are serin-threonine kinases, which act as molecular switches, regulating multiple processes
in cell division including spindle organization, chromosome alignment, the spindle assembly checkpoint,
cytokinesis, and the abscission checkpoint [43]. The family of AURKs includes aurora kinase A (AURKA,
STK15), aurora kinase B (AURKB, STK12), and aurora kinase C (AURKC, STK13) [43,44]. AURKs contain an
N-terminal domain (39–139 aa), a kinase domain (250–300 aa), and a C-terminal domain (15–20 aa) [45].
AURK overexpression is common in EOC and has been correlated with prognostic value.
There is enough evidence of cross-talk between AURKs and p53. Furthermore, AURKA interacts
with proteins involved in apoptosis, specifically p73, a protein of the family of p53, implicated in the
regulation of cell cycle and apoptosis. An in vitro study demonstrated that inhibition of AURKA in a
p53-deficient cell line results in the expression of genes associated with p73-mediated apoptosis [46].
DNA damage induces activation of checkpoint kinase 1 (CHEK1), which then transduces the
checkpoint signal and facilitates cell cycle arrest and DNA damage repair. It has been described as a
synergistic anti-tumoral effect between AURKA and CHEK1 inhibitors in EOC [47]. Expression of
AURKA and CHEK1 has been associated with dismal prognosis in early-stage EOC. Based on that,
molecular analyses of the pathways in which these genes participate may be used to select patients for
whom AURKA inhibitors would be effective.
Within the context of AURK inhibition in EOC, a large cohort of 240 patients with recurrent
high-grade EOC who were referred to the phase I clinical trials program has been analyzed
retrospectively [48]. Targeted agents included bevacizumab, vascular endothelial growth factor
(VEGF) receptor inhibitors, and other compounds targeting the PI3K/AKT/mTOR, MAPK, Src,
Wee1, and AURKA signaling pathways. Chemotherapy plus bevacizumab-based or AURKA kinase
inhibitor-based regimens were potentially effective and yielded a median PFS of more than 6 months,
which is indicative of potential benefit deriving from AURKA inhibitors. A preclinical study in EOC
cell lines demonstrated that the selective small inhibitor alisertib inhibits epithelial–mesenchymal
transition via the PI3K/AKT/mTOR and sirtuin-1 mediated pathways [49]. The selectivity in the
inhibition of AURKA may be related to a more favorable toxicity profile and a better therapeutic index
than pan-AURK inhibitors.
In vitro inhibition of AURKA with alisertib decreased the expression of PARP and BRCA1/2
and stimulated the NHEJ repair pathway [50]. Following these findings, in vivo studies confirmed
that AURKA inhibition elevated phosphorylated DNA-PKcs and decreased PARP levels. Alisertib
treatment alone or combined with paclitaxel significantly reduced the growth and dissemination of
orthotopic EOC xenografts. The potent synergy between alisertib and paclitaxel in vitro suggests that
the combination of these agents may be more effective than either drug alone [51].
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ENMD-2076 has selective activity against AURKA, as well as kinases involved in angiogenesis [52].
The rationale for a phase II trial of ENMD-2076 in OCCC was that apart from the strong expression
of VEGF in this histological subtype, the overexpression of AURKA had also been associated with
chemoresistance [53,54].
The pan-AURK inhibitor danusertib hydrochloride shows a dominant AURKB kinase
inhibition-related cellular phenotype and mechanism of action in cells in vitro and in vivo. In a
phase I trial, 56 patients received escalating doses of danusertib (24 h infusion every 14 days) without
granulocyte colony-stimulating factor (G-CSF). Among them, one patient with refractory EOC had 27%
tumor regression and 30% biochemical response, suggesting a potential activity in this setting [55].
Finally, the pan-AURK inhibitor tozasertib not only causes cytokinesis defects through AURK
inhibition but is also a potent inhibitor of necroptosis, a cell death process regulated and executed by
the RIPK1, RIPK3, and MLKL signaling axis. Tozasertib may enhance carboplatin activity by MTT
proliferative assay in both platinum-sensitive and platinum-resistant EOC cell lines, regardless of
p53 status [56]. A low dose of tozasertib promotes paclitaxel-induced apoptosis and is effective in
paclitaxel-resistant cells [57]. Furthermore, the combination of tozasertib with valproic acid led to a
synergistic effect on gynecologic cancer cells [58].
5. Metformin and Ovarian Cancer
Metformin was officially introduced to diabetes treatment in 1957 and still represents a
well-recognized therapeutic choice for type 2 diabetes [59]. The preclinical anti-cancer efficacy of
metformin has been demonstrated mainly in breast cancer [60]. In vitro studies have demonstrated that
metformin may stimulate AMP-activated protein kinase activation in breast cancer cells, with inhibition
of the mTOR pathway [61]. In this regard, several inhibitors of the PI3K/Akt pathway are under
investigation in animal models and clinical trials in the field of breast cancer [62,63].
Similarly, metformin inhibits the AMPK-dependent growth of multiple EOC cell lines and inhibits
several receptor tyrosine kinases, such as human epidermal growth factor receptor 4 (HER4), epidermal
growth factor receptor (EGFR), and platelet-derived growth factor receptor (PDGF-R) [64]. Treatment
with metformin in vitro and in vivo in murine experiments resulted in decreased angiogenesis in
metastatic tissues and attenuated ovarian cancer cell adhesion [65,66]. It has also been demonstrated
that the reduction in neovascularization following metformin treatment can be driven by blockage
of the mTOR signaling pathway [67,68]. Furthermore, metformin targets ALDH+ EOC stem cell
populations in vitro, leading to suppressed angiogenesis, proliferation, and tumor growth [69].
Programmed cell death is mediated by several protein factors that include the Bcl-2 protein
family and the caspase group of cysteine proteases. The upregulation of the Bax (Bcl-2 family
member) increases the activity of the caspases and enhances the apoptotic activity. The inhibition of
caspase-3 is included in the mechanism by which insulin promotes apoptosis. Apart from Bax, insulin
downregulates Bad, which prevents programmed cell death. Many preclinical EOC studies correlate
Bcl-2-regulated apoptosis to metformin’s chemosensitizing effects [65,70,71]. The chemosensitizing
effect of metformin seems to be correlated with p53 function. In the presence of p53, metformin
suppresses hexokinase II (glycolytic enzyme) and pyruvate dehydrogenase kinase (anti-apoptotic
serine/threonine kinase) [72]. As a result, EOC cells are sensitized to metformin. Furthermore,
metformin may re-sensitize platinum- or paclitaxel-resistant EOC cells to chemosensitive cells, either
by induction of autophagy or via its anti-inflammatory properties [67,73].
While metformin has wide anti-cancer effects in preclinical models, results of studies evaluated
the association between metformin use and survival in ovarian cancer patients with type 2 diabetes are
inconclusive [74–78]. So far, sufficient evidence verifying metformin use in ovarian cancer prevention
is lacking. Register-based epidemiological studies of the incidence of ovarian cancer in patients taking
metformin are depicted in Table 3.
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Table 3. Incidence of ovarian cancer in metformin users among women with type 2 diabetes.
Publication
Reference Design
Cancer
Patients (n)
Ovarian Cancer
Patients (n)
Metformin
Users (n)
Reference
Group Outcome
[79] Case-controlanalysis 1611 85 41
Women with
T2D and no
prior metformin
use
OR 0.38 (95% CI 0.18–0.81)
when ≥10 prescriptions
of metformin;
OR 0.59 (95% CI 0.25–1.41)
when <10 prescriptions
of metformin
[80] Observationalstudy 479,475 3201 601
Women with
T2D and no use
of metformin
aHR 0.66 (95% CI 0.59–0.73);
p < 0.01
[81] Retrospectivecohort study NA 303 303
Women with
T2D using other
oral ADM
Full cohort aHR 1.02
(95% CI 0.72–1.45);
Case-control aHR 0.91
(95% CI 0.61–1.34)
OR: odds ratio; CI: confidence interval; aHR: adjusted hazard ratio; ADM: anti-diabetic medication.
6. Endometriosis and Ovarian Cancer Risk
Both endometriosis and ovarian cancer have certain pathogenic similarities, and share similar risk
factors [82]. The prevalence of ovarian cancer that appears in patients with endometriosis is greater
than sporadic ovarian cancer in the general population. Women with endometriosis have an increased
risk for certain subtypes of EOC, such as OCCC and EnOC [83,84].
There is strong evidence of a genetic link between endometriosis and ovarian cancer. Mutations in
ARID1Ahave been found in several cancers, and SWI/SNF-associated gene mutations occur in approximately
20% of all malignancies, whereas the most frequent mutations in ARID1A are found in OCCC (46–57%)
and EnOC (approx. 30%) [85–88]. Mutations in ARID1A result in the loss of BRG-associated factor 250a
(BAF250a), a protein with an important role in cell proliferation and tumor suppression. It has been shown
that loss of BAF250a presumably occurs at an early stage in carcinogenesis, as has been observed in a subset
of benign endometriotic cysts of the ovary and deep-infiltrating endometriosis. Samartzis et al. described a
complete loss of BAF250a in benign endometriotic lesions. Interestingly, the stromal BAF250a expression
was lower in ovarian endometriosis, as compared to eutopic endometrium, peritoneal endometriosis,
and deep-infiltrating endometriosis [89–91]. Identification of synthetic lethal targets that are conferred
by these SWI/SNF-associated mutations on cancer cells requires further investigation and has important
therapeutic potential. Targeting of sustained proliferative pathways, such as the PI3K/AKT/mTOR and
the YES1/SRC tyrosine kinase pathways, or metabolic alterations, such as the glutathione biogenesis
pathway, in ARID1A-deficient OCCC should be considered in future clinical trials. Such synthetic
lethal agents in the ARID1A mutant setting are currently in clinical development. The inhibitory effects
on residual SWI/SNF function, specifically via reduced ARID1B expression, may explain the enhanced
sensitivity of ARID1A mutant cells to bromodomain and extraterminal domain (BET) inhibitors.
As such, patients with ARID1A mutant OCCC may benefit from inhibitors of the BET family of proteins
added to their treatment regimen.
The discovery of frequent somatic phosphatase and tensin homolog (PTEN) mutations and loss of
heterozygosity at the 10q23 PTEN locus in EnOC, along with an absence of such mutations in other
histological subtypes, suggests a key role for PTEN in the etiology of this subtype. Using a mouse
model, Dinulescu et al. induced EnOC and saw that expression of oncogenic KRAS or conditional PTEN
deletion within the ovarian surface epithelium forms endometriotic precursor lesions. These alterations
led to the development of invasive EnOC [92].
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EZH2 is a histone methyltransferase that sets the H3K27me3 histone mark, a repressor of
the transcriptional machinery. EZH2 also enhances angiogenesis, with a key role in ovarian
carcinogenesis [93]. Higher levels of EZH2 correlated to a worse prognosis for EOC patients [94].
Due to in vivo-detected toxicity of first-generation EZH2 inhibitors, novel EZH2 inhibitors are currently
investigated [95]. The NRG-GY-014 phase II clinical trial assessing the EZH2-inhibitor tazemetostat in
recurrent EnOC, OCCC, and/or recurrent low-grade endometrioid endometrial carcinoma is currently
recruiting [96].
There are several studies where differential expression of miRNAs has been studied in either
endometriosis or ovarian cancer. Several differentially expressed miRNA in endometriosis compared
to ovarian cancer have been found, mainly linked with epithelial–mesenchymal transition [97].
Two common miRNAs overexpressed in both diseases were miR-325 and miR-492. While the
expression of miR-325 was upregulated in both diseases, this was more prominent in ovarian cancer,
suggesting that miR-325 could have a role in the transition from endometriosis to ovarian cancer [97].
Among well-investigated epigenetic drugs in the field of ovarian cancer are histone
deacetyltransferase (HDAC) inhibitors, which work by increasing the level of acetylated histones thus
reactivating silenced tumor suppressor genes. Currently, only three HDAC inhibitors—vorinostat,
romidepsin, and panobinostat—have been approved by the FDA [98]. HDAC inhibitors seem to be
effective particularly in combination with other anti-cancer drugs and/or radiotherapy. A combination
of DNA methyltransferases (DNMTs) and HDAC inhibitors has been shown to overcome platinum
resistance in ovarian cancer. It has been demonstrated that the DNMT inhibitor decitabine may lead to
demethylation of many genes, including BRCA1 [99].
Hydralazine is a non-nucleoside DNA-demethylating drug with an anti-hypertensive effect.
The mechanism of action of hydralazine is still a controversial issue, as some groups claimed that
it binds to the catalytic site of DNMTs, while others reported that it reduces DNMT1 and DNMT3a
expression via the extracellular signal-regulated kinase (ERK) pathway inhibition. This drug, combined
with valproic acid, was assessed in refractory solid tumors, including ovarian cancer [100].
Another combination approach with good response refers to epigenetic inhibitors and
immunotherapy. In a mouse model of EOC, DNMT and HDAC inhibitors improved the response to
immune checkpoint therapy. Specifically, the DNMT inhibitor 5-azacytidine increased the number
of CD45+ immune cells and the percentage of natural killer cells and active CD8+ cells in the
microenvironment. As a result, tumor burden was reduced and survival was prolonged. A triple
combination therapy consisting of a DNMT, HDAC, and an immune checkpoint inhibitor provided the
greatest efficacy [101].
An overview of current clinical trials mainly regarding OCCC using an ARID1A-related treatment
approach is available in Table 4.
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Table 4. Clinical trials in gynecological cancer using an ARID1A-related treatment approach (www.clinicaltrials.gov).
Study/Status Phase Patients n Agent Design Primary Outcome
NCT04065269/Recruiting II 40 AZD6738 (ATR inhibitor)
+ olaparib
Experiment 1A: AZD6738;
relapsed ovarian (fallopian tube/primary peritoneal) and endometrial clear cell carcinomas
with loss of ARID1A expression
Experiment 1B: AZD6738 + olaparib;
(depending on response rate in cohort 1A);
relapsed ovarian (fallopian tube/primary peritoneal) and endometrial clear cell carcinomas
with loss of ARID1A expression
Experiment 2: AZD6738 + olaparib;
relapsed ovarian (fallopian tube/primary peritoneal) and endometrial clear cell carcinomas
without loss of ARID1A expression
Experiment 3: AZD6738 + olaparib;
relapsed rare gynecological cancers (endometrioid ovarian carcinoma, endometrioid
endometrial carcinoma, cervical adenocarcinoma, cervical squamous, ovarian carcinosarcoma
and endometrial carcinosarcoma) regardless of ARID1A status
ORR
NCT02059265/Active, not
recruiting II 35 Dasatinib
Dasatinib OD, days 1–28, until PD or unacceptable toxicity;
endometrial clear cell adenocarcinoma;
ovarian clear cell cystadenocarcinoma;
recurrent fallopian tube carcinoma;
recurrent ovarian carcinoma;
recurrent primary peritoneal carcinoma;
recurrent uterine corpus carcinoma;
ORR
NCT03297424/Recruiting I/II 166 PLX2853 (BRD4 inhibitor)
phase 1b (dose escalation):
up to 30 subjects with advanced malignancies
phase 2a (dose expansion):
5 expansion cohorts in total;
expansion cohorts 1–4: either 10 or 29 subjects per cohort: advanced SCLC, uveal melanoma,
OCCC, and any other advanced malignancy with a known ARID1A mutation;
expansion cohort 5: up to 20 subjects may be enrolled for NHL
1. AEs;
2. Pharmacokinetics of
PLX2853 (AUC, Cmax,
Tmax, t1/2);
3. Dose-limiting toxicity;
4. Response by RECIST
1.1 (solid tumors) or
Lugano criteria (NHL)
NCT03348631/Suspended II 86 Tazemetostat (EZH2inhibitor)
Tazemetostat BID, days 1–28, until PD or unacceptable toxicity;
FIGO grade 1/2 endometrial endometrioid; adenocarcinoma;
recurrent endometrial endometrioid; adenocarcinoma;
recurrent ovarian carcinoma;
recurrent ovarian clear cell adenocarcinoma;
recurrent ovarian endometrioid; adenocarcinoma;
recurrent uterine corpus carcinoma
ORR
NCT01914510/Completed II 40
ENMD-2076 (oral
anti-angiogenic and
anti-proliferative
kinase inhibitor)
ENMD-2067 275 mg, OD, days 1–28;
starting dose of 250 mg, OD, days 1–28 in subjects with a body surface area of less than 1.65 m2
1. 6 month PFS rate;
2. CR rate;
3. PR rate
ATR: ataxia telangiectasia and Rad3-related kinase; ORR: overall response rate; OD: once a day; PD: progressive disease; BRD4: bromodomain-containing protein 4; SCLC: small-cell
lung cancer; OCCC: ovarian clear cell carcinoma; NHL: non-Hodgkin lymphoma; AEs: adverse events; AUC: area under the concentration–time curve; Cmax: maximum observed
concentration; Tmax: time to peak concentration; t1/2: half-life; RECIST: Response Evaluation Criteria in Solid Tumors; EZH2: enhancer of zeste homolog 2; BID: twice a day; FIGO:
International Federation of Gynecology and Obstetrics; PFS: progression-free survival; CR: complete response; PR: partial response.
J. Pers. Med. 2020, 10, 41 11 of 20
7. Management of Malignant Ovarian Germ Cell Tumors (MOGCTs)
Non-epithelial ovarian cancers are a group of uncommon, histologically, and clinically distinct
tumors, with favorable prognosis as compared with the majority of their epithelial counterparts [102].
The two most frequently diagnosed non-epithelial ovarian cancers are MOGCTs and SCSTs, with several
histological subtypes [103]. SCSTs arise from the sex cord and ovarian stroma and comprise granulosa
cell tumors—the most common subtype, subdivided into juvenile and adult types—Sertoli–Leydig
cell tumors, theca cell tumors and rare SCSTs with annular tubules. Ovarian small-cell cancers
(hypercalcemic and non-hypercalcemic types) and sarcomas are extremely rare and aggressive cancers
with dismal prognosis [27,104].
MOGCTs account for only 2–5% of all ovarian cancers. They typically occur in children and
young women aged 10–30 years, with a peak incidence in the teenage years [105]. Their rarity in
postmenopausal women can cause initial diagnostic uncertainty and lead to delayed or suboptimal
treatment [106]. MOGCTs are divided into dysgerminomas and non-dysgerminomas including
primarily yolk sac tumors and immature teratomas. The presence of bilateral ovarian involvement
suggests dysgerminoma or mixed histology, with a predominant dysgerminoma element. Signs and
symptoms of MOGCTs usually include abdominal pain with a palpable pelvic abdominal mass (85%),
followed by abdominal distension (35%), fever and vaginal bleeding (10% each). Those patients may
also exhibit symptoms of pregnancy or precocious puberty, related to β-human chorionic gonadotropin
production by the tumor. Adverse prognostic factors include advanced-stage, residual tumor after
salvage surgery, non-dysgerminoma histology, as well as elevated Ca125 and age > 40 years at initial
diagnosis. Even advanced/metastatic disease is potentially curable, at least in 75% of cases [103].
Surgical staging remains the cornerstone in the management of MOGTs. Surgical procedures
include exploratory laparotomy, peritoneal washing, omental biopsy, unilateral oophorectomy,
and selective removal of enlarged lymph nodes. Hysterectomy and bilateral salpingo-oophorectomy
and can be considered in patients who do not wish to preserve fertility [107]. This is not always feasible,
given that MOGCTs typically affect women of childbearing age. Approximately 60–70% of MOGCTs
are diagnosed at stage I. These tumors can be cured without postoperative chemotherapy. Fertility
sparing surgery can be also proposed in advanced stages after careful discussion with young patients
who desire pregnancy [108]. In the case of residual teratoma, second-look surgery is therapeutically
indicated [109]. Current approaches to the treatment are summarized in Table 5.
Table 5. Management options for malignant ovarian germ cell tumors (MOGCTs).
Dysgerminomas Immature Teratomas Other
Stage I USO with preservation of the contralateral ovary and uterus for fertility;TAH-BSO is acceptable if childbearing has been completed
Stage IA No ACT
G1: No ACT
ACTG2: Consideration of ACT
G3: ACT
Stage IB/C ACT
Stage II
USO with preservation of the contralateral ovary and uterus for fertility;
TAH-BSO is acceptable if childbearing has been completed;
ACT
Stage III/IV
USO with preservation of the contralateral ovary and uterus for fertility;
TAH-BSO is acceptable if childbearing has been completed;
UDS-ACT;
NACT-IDS when indicated
Recurrent tumors Palliative chemotherapy
MOGCTs: malignant ovarian germ cell tumors; USO: unilateral salpingo-oophorectomy; TAH-BSO: total abdominal
hysterectomy and bilateral salpingo-oophorectomy; ACT: adjuvant chemotherapy; G: grade; UDS: upfront debulking
surgery; NACT: neoadjuvant chemotherapy; IDS: interval debulking surgery.
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The bleomycin/etoposide/cisplatin (BEP) regimen is the preferred adjuvant chemotherapy. There is
consensus that three cycles of BEP prevent recurrence in cases with completely resected disease. Four to
five cycles are recommended for patients with macroscopic residual disease; nevertheless, this should
be continued for up to six cycles in those with ongoing radiological or biochemical response [103].
The ongoing chemotherapy phase 3 trials, summarized in Table 6, may change the clinical management
of MOGCTs. The long-term side effects of platinum-based chemotherapy for MOGCTs are mostly
irreversible and the severity is related to the chemotherapy cumulative dose. Identification of patients
more likely to experience cisplatin-related toxicities could be based on several single-nucleotide
polymorphisms [110].
Table 6. Phase III trials of combination chemotherapy in MOGCTs still recruiting patients.
Study Population Patients n Treatment Arms Primary Endpoint
TIGER
(NCT02375204) Relapsed or refractory disease 420
Arm A:
CDCT (TIP)
Arm B:
HDCT plus ASCT with TI-CE
OS
MOGCT-01
(NCT02429687)
Stage IIA-IVB,
adjuvant treatment 129
Arm A:
PT
Arm B:
BEP
PFS
ANZUP-1302
(NCT02582697)
Stage IV,
intermediate or poor prognosis as
defined by IGCCC classification
500
Arm A:
accelerated BEP
Arm B:
standard BEP
PFS
NCT03067181
Low-risk stratum:
Age (years):
<50 years;
Sites:
ovarian immature teratoma, GCT (all
sites);
Stage:
Stage I
Standard risk 1:
Age (years):
<11;
Sites:
ovarian, testicular, or extragonadal
site;
Stage:
FIGO stage II-IV; YST, EC, or
choriocarcinoma
Standard risk 2:
Age (years):
>= 11 and <25;
Ovarian:
FIGO stage IC, II/III;
YST, EC, or choriocarcinoma;
Testicular:
AJCC stage II/III, IGCCC good risk;
YST, EC, or choriocarcinoma;
Extragonadal:
COG stage II;
YST, EC, or choriocarcinoma
1680
Arm A:
bleomycin/carboplatin/etoposide
(up to 4 cycles)
Arm B:
BEP (up to 4 cycles)
Arm C:
bleomycin/carboplatin/etoposide
(up to 3 cycles)
Arm D:
BEP (up to 3 cycles)
Experiment (low risk):
observation
1. OS;
2. PFS
NCT03418844
MOGCTs
SCSTs
Remission > 2 years following
initial treatment
480
Self-questionnaires of living
conditions and QoL;
Interest group:
patients treated with
chemotherapy
Control group:
patients not treated with
chemotherapy
1. Chronic fatigue;
2. Late sequelae of CTH (cardiac,
pulmonary disorders);
3. QoL
MOGCTs: malignant ovarian germ cell tumors; CDCT: conventional-dose chemotherapy; TIP:
paclitaxel/ifosfamide/cisplatin; HDCT: high-dose chemotherapy; ASCT: autologous stem cell transplant; TI-CE:
paclitaxel plus ifosfamide followed by high-dose carboplatin and etoposide; OS: overall survival; PT:
paclitaxel/cisplatin; BEP: bleomycin/etoposide/cisplatin; PFS: progression-free survival; IGCCC: international
germ cell cancer consensus classification; GCT: germ cell tumors; FIGO: International Federation of Gynecology
and Obstetrics; YST: yolk sac tumor; EC: embryonal carcinoma; AJCC: American Joint Committee on Cancer; COG:
Children’s Oncology Group; SCSTs: sex cord-stromal cell tumors; QoL: quality of life; CTH: chemotherapy.
Recurrences usually occur within two years of initial diagnosis and typically relapse peritoneal
cavity and retroperitoneal lymph nodes. The salvage rate for chemotherapy in patients with MOGCTs
is approximately 50%, and recommended regimens include vinblastine, ifosfamide, and cisplatin;
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etoposide, ifosfamide, and cisplatin; and paclitaxel, ifosfamide, and cisplatin [111,112]. Secondary
cytoreductive surgery could be performed in selected patients with recurrent disease.
Somatic mutations in MOGCTs are not a frequent phenomenon. The low mutation rate, the p53
wild-type signature, and other somatic copy number aberrations support the resemblance of MOGCTs
to testicular germ cell tumors. An analysis of 87 MOGCTs identified recurrent mutations in KIT and
KRAS, along with frequent focal amplifications of PIK3CA and AKT1 in yolk sac tumors [113]. However,
the clinical efficacy of any targeted treatment has not been reported in unselected patient populations.
The lack of efficacy of imatinib in MOGCTs is probably related to the frequent mutations in the KIT
enzymatic site, which leads to reduced sensitivity to imatinib blockade [114]. Further investigation of
CDK4/6 inhibition for the treatment of teratoma is required based on the preliminary results indicating
the safety and potential clinical benefit [115]. Similarly, immune checkpoint inhibitors in MOGCTs
need to be unraveled [115,116].
8. Conclusions and Future Perspectives
Since inflammatory and epigenetic processes play a predominant role in the pathogenesis
of endometriosis-associated ovarian carcinomas, immunotherapy as well as epigenetic treatment
approaches open the way to more personalized and adaptive therapies. A combination of multiple
biomarker changes rather than a single gene or marker is involved in the initiation and progression of
either disease. Genetic risk has an important impact on ovarian cancer. The evolution of NGS allows
a rapid evaluation of multiple cancer susceptibility genes at similar costs to single gene sequencing.
Germline genetic testing should be offered to all newly diagnosed patients with EOC to detect gPVs in
all genes associated with EOC susceptibility. Furthermore, tumor sequencing to identify potentially
targetable somatic mutations is increasingly being used in high-grade serous EOC and influences
decisions on patient treatment. HR deficiency remains a strong predictor of clinical benefit from
PARP inhibitors. Beyond germline, PARP inhibitors may be effective in somatic BRCA1/2 mutations
as well. Among other tumors, high-grade serous EOCs have shown a high frequency of phenotypes
with a gain of function of AURK and a loss of function of p53. An understanding of the functional
diversity of AURKs could help to evaluate their relevance as potential therapeutic targets. Anti-mitotic,
anti-angiogenic, and anti-inflammatory effects of metformin are well studied in vitro. Ongoing clinical
trials will potentially clarify the role of metformin in ovarian cancer treatment. MOGCTs are rare
entities, treated with surgery and possibly platinum-based regimens based on the stage of the disease.
Preclinical work on MOGCTs is warranted to allow investigation of novel drug targets.
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